Upregulation of NDUFAF2 in Lung Adenocarcinoma Is a Novel Independent Prognostic Biomarker

Table 1

Correlation between NDUFAF2 expression and baseline clinicopathologic characteristics of LUAD patients from the TCGA database.

Characteristic	Low expression of NDUFAF2	High expression of NDUFAF2
	256	257
Age, (%)			0.928
≤65	125 (24.3%)	123 (23.9%)
>65	131 (25.7%)	134 (26.1%)
Gender, (%)			0.892
Female	139 (27.1%)	137 (26.7%)
Male	117 (22.8%)	120 (23.4%)
Pathologic stage, (%)			<0.001
Stage I	156 (30.9%)	118 (23.4%)
Stage II	57 (11.3%)	64 (12.7%)
Stage III	26 (5.1%)	58 (11.5%)
Stage IV	13 (2.6%)	13 (2.6%)
T stage, (%)			0.002
T1	102 (20%)	66 (12.9%)
T2	121 (23.7%)	155 (30.4%)
T3	24 (4.7%)	23 (4.5%)
T4	6 (1.2%)	13 (2.5%)
N stage, (%)			<0.001
N0	184 (36.7%)	146 (29.1%)
N1	38 (7.6%)	57 (11.4%)
N2	24 (4.8%)	50 (10%)
N3	1 (0.2%)	1 (0.2%)
M stage, (%)			1.000
M0	165 (44.7%)	179 (48.5%)
M1	12 (3.3%)	13 (3.5%)
Smoker, (%)			0.160
No	31 (6.2%)	43 (8.6%)
Yes	219 (43.9%)	206 (41.3%)
OS event, (%)			0.001
Alive	181 (35.3%)	145 (28.3%)
Dead	75 (14.6%)	112 (21.8%)
Age, median (IQR)	66 (59, 73)	66 (59, 72)	0.652